Details of the Drug Combination

General Information of Drug Combination (ID: DCBO7UC)

Drug Combination Name

Meglumine antimoniate Pentoxifylline

Indication

Disease Entry	Status	REF
Leishmaniasis	Phase 2	[1]

Component Drugs

Meglumine antimoniate DMINAG4

Pentoxifylline DMU3DNC

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Meglumine antimoniate

Disease Entry	ICD 11	Status	REF
Leishmania braziliensis infection	1F54.2	Approved	[2]

Indication(s) of Pentoxifylline

Disease Entry	ICD 11	Status	REF
Alcoholic hepatitis	DB94.1	Approved	[3]
Intermittent claudication	BD40.00	Approved	[4]
Type-1 diabetes	5A10	Approved	[3]
Peripheral vascular disease	BD4Z	Investigative	[3]

Pentoxifylline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	.	[5]
------------------------------------------------------------------------------------

Pentoxifylline Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Pentoxifylline Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Metalloproteinase inhibitor 1 (TIMP1)	OTOXC51H	TIMP1_HUMAN	Increases ADR	[7]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases ADR	[7]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Increases ADR	[7]
Matrix metalloproteinase-14 (MMP14)	OT9C197Z	MMP14_HUMAN	Increases ADR	[7]
Perforin-1 (PRF1)	OTFVXD7H	PERF_HUMAN	Increases ADR	[7]
Granzyme B (GZMB)	OTPPVIRS	GRAB_HUMAN	Increases ADR	[7]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases ADR	[7]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases ADR	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Cutaneous Leishmaniasis	DCBLTV8	N. A.	Phase 1	[8]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02530697) The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Pentoxifylline FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7095).
5	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
6	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8.
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	ClinicalTrials.gov (NCT01464242) Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis